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PACAP38 in human models of primary
headaches
Håkan Ashina, Song Guo, Anne L. H. Vollesen and Messoud Ashina*
Abstract
Background: To review the role of PACAP38 in human models of primary headaches, discuss possible mechanisms
of PACAP38-induced migraine, and outline future directions.
Discussion: Experimental studies have established PACAP38 as a potent pharmacological “trigger” molecule of
migraine-like attacks. These studies have also revealed a heterogeneous PACAP38 migraine response in migraine
without aura patients. In addition, findings from brain imaging studies have demonstrated neuronal and vascular
changes in migraine patients both ictally and interictally after PACAP38 infusion.
Conclusion: Human migraine models have shed light on the importance of PACAP38 in the pathophysiology of primary
headaches. These studies have also pointed to the PAC1 receptor and the PACAP38 molecule itself as target sites
for drug testing. Future research should seek to understand the mechanisms underlying PACAP38-induced
migraine. The results from an ongoing proof of concept randomized clinical trial may reveal the therapeutic
potential of anti-PAC1 receptor antibodies for migraine prevention.
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Background
Much research effort has been devoted to studying
the pathophysiology of primary headaches using
human experimental models, which have led to the
discovery of novel headache-eliciting signaling path-
ways and new drug targets [1]. In this context, pituit-
ary adenylate cyclase-activating polypeptide (PACAP)
has over the past decade emerged as a key signaling
molecule implicated in migraine [2] and possibly also
in cluster headache [3].
PACAP belongs to the glucagon/secretin superfamily
of peptides together with vasoactive intestinal polypep-
tide (VIP) [4] and exists in two bioactive forms: a 38
amino acid form (PACAP38) and a truncated 27 amino
acid form (PACAP27) [5]. PACAP38 is present in first-
order neurons in the trigeminal ganglion [6], second-
order neurons in the trigeminal nucleus caudalis (TNC)
[7], and dorsal horn of the human spinal cord [8]. In
addition, PACAP38 has also been identified in the otic
and sphenopalatine ganglia [9], as well as in the cerebral
cortex, cerebellum, brain stem and hypothalamus [10].
The effect of PACAP38 is mediated through three
G-protein coupled receptors (PAC1, VPAC1–2) [11],
two of which (VPAC1–2) hold equal affinity for
PACAP38 and VIP, while the PAC1 receptor has a
much higher affinity for PACAP38 [12]. The distribu-
tion of all three receptors has been documented in
trigeminal, otic and superior cervical ganglia [13], as
well as in cerebral and meningeal arteries [14]. Upon
activation, all receptors cause downstream production
of cyclic adenosine monophosphate (cAMP) through
adenylate cyclase (AC) stimulation [15]. Studies have
reported that the VPAC1–2 receptors play a role in
vasodilation and mast cell degranulation [16–20],
whereas one study in rats implicated the PAC1 recep-
tor in pro-nociceptive transmission [21].
The headache-inducing effect of PACAP38 has been
extensively studied in both healthy volunteers and mi-
graine without aura (MO) patients. This has sparked an
interest in pursuing specific treatment options targeting
the PACAP38 molecule [22] or its PAC1 receptor [23].
Future randomized clinical trials (RCTs) will fully un-
cover whether PACAP38 or PAC1 receptor blockade
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could be a promising new approach in treating primary
headaches.
In this review, we focus on human headache models
using PACAP38 as a pharmacological “trigger” of migraine-
like attacks. We then consider methodological aspects and
limitations. Finally, we outline future perspectives and the
therapeutic potential of anti-PACAP38 treatment to ad-
dress unmet patient needs.
PACAP38 migraine models
Birk et al. [24] for the first time systematically investigated
PACAP38-induced headache and cerebral hemodynamics
in 12 healthy volunteers. In this and the following
described studies, healthy volunteers were identified as
subjects who had no prior history of migraine and no
first-degree relatives suffering from migraine. Ten out of
12 participants (83%) reported mild to moderate headache
following PACAP38 infusion over 20 min, while no effect
was observed on regional cerebral blood flow. There was a
minor dilation of the middle cerebral artery (MCA) re-
corded by a transcranial Doppler (TCD) after PACAP38
infusion. However, certain limitations of the TCD method
should be acknowledged. The TCD method assesses MCA
velocity, which is dependent on the blood flow and the
cross-sectional area of the artery. To interpret reduced
velocity as arterial dilation, it requires that cerebral blood
flow is constant despite heart rate variability and different
angles of insonation. A more detailed description of
methodological considerations on arterial measure-
ments by TCD has recently been reviewed [25]. In
healthy volunteers, the dose-response to 5, 10, 15, and
20 pmol kg−1 min−1 was investigated in three partici-
pants [24]. In all three cases the infusion was aborted
after 10 pmol kg−1 min−1 due to 40–50% increases in
heart rate – probably compensatory to the vasodilating
effect of PACAP38. Following these observations,
which have recently been confirmed in a dose-response
study [26]; a dose of 10 pmol kg−1 min−1 is considered
the optimal dose for experimental provocation studies.
Given that experimentally provoked attacks are not
spontaneous according to the International Headache
Society (IHS) criteria [27], different criteria for experi-
mentally induced migraine attacks have been introduced
[28]. The provoked migraine attacks should either fulfill
IHS criteria C and D for MO [25] or mimic the usual
migraine attack experienced by the patient and subse-
quent response to treatment with acute rescue medica-
tion [28]. To investigate the migraine-inducing effects of
intravenous PACAP38 infusion, Schytz et al. [29] per-
formed a double-blind, placebo-controlled crossover
studies in 12 healthy volunteers and 12 MO patients.
The authors hypothesized that PACAP38 infusion would
induce headache in controls and migraine-like attacks in
MO patients. All controls reported headache after
PACAP38 infusion, while two controls also experienced
migraine-like attacks. In MO patients, 7 out of 12
subjects (58%) reported migraine-like attacks after
PACAP38 infusion compared with zero after placebo.
Interestingly, the median time to peak headache score
(4 h, range 0–12 h) in MO patients following PACAP38
provocation was similar to those reported in calcitonin
gene-related peptide (CGRP) (5 h, range 2-9 h) and gly-
ceryl trinitrate (GTN) (5.5 h, range 3–10 h) provocation
studies [30, 31]. Moreover, the authors assessed the vas-
cular effects of PACAP38 infusion on the MCA by TCD
and the superficial temporal artery (STA) by dermascan
ultrasonography during the hospital phase of the study
(0-2 h post infusion) [29]. In MO patients, PACAP38 in-
fusion caused a modest MCA dilation of 9.5% compared
to baseline, while a more marked dilation of 37.5% was
found in the STA. This study yielded two important
findings. First, PACAP38 induced migraine-like attacks
in 58% of MO patients, while no attacks were reported
after placebo. Secondly, prolonged cranial artery dilation
suggested a possible role of vascular mechanisms in
PACAP38-induced migraine.
Magnetic resonance angiography (MRA) constitutes a
superior method for measuring vessel diameter com-
pared to TCD and provides more precise measurements
of circumferential arterial changes [32]. All of the de-
scribed provocation studies using TCD and MRA only
assessed vascular effects in the middle meningeal artery
(MMA), STA, and MCA [24, 29, 33, 34]. Using MRA, a
double-blind, placebo-controlled study investigated the
effect of PACAP38 infusion on the MCA and MMA in
healthy volunteers [33]. The MMA was selected because
it is the main artery supplying the dura mater and one
previous study demonstrated MMA (but not MCA)
involvement in CGRP-induced headache in healthy
volunteers [35]. The major finding of the MRA study
[33] was that PACAP infusion caused a long-lasting dila-
tion (> 5 h) of the MMA co-occurring with headache,
while no effect was found on the MCA circumference.
In addition, subcutaneous injection of sumatriptan re-
versed the MMA dilation and headache, whereas the
MCA circumference was unaltered. It is possible that
PACAP38 does not reach its receptors on the smooth
muscle cells in the MCA. In support, in vitro studies
[36] reported a vasodilatory effect of PACAP38 on the
rat and human MCA when applied abluminally but not
luminally. The question is whether MMA dilation with
co-occurring headache following PACAP38 infusion and
the subsequent MMA constriction with co-occurring
headache relief following sumatriptan reflect the import-
ance of the MMA in migraine generation and cessation.
It should be noted that sumatriptan is a 5-HT1B/1D re-
ceptor agonist that was originally developed as vasocon-
strictor acting through receptor binding on cranial
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vessels [37]. However, its exact mechanism of action in
relation to migraine remains a highly debated topic [38].
In healthy volunteers, subcutaneous injection of suma-
triptan caused constriction of the STA, MMA, and
MCA [39]. However, the same authors found a
significantly smaller intracerebral arterial constriction
compared with the constriction of extracerebral arter-
ies – suggesting a primarily peripheral site of action
for triptans. In the context of human provocation
studies, subcutaneous injection of sumatriptan caused
co-occurring MMA constriction and amelioration of
migraine-like attacks following both PACAP38 [33]
and CGRP [40] infusion. In both provocation studies
[33, 40], no sumatriptan effect was found on the
MCA circumference.
An interesting aspect to consider is that even
though VIP belongs to the same family of peptides as
PACAP38 [41], it does not induce migraine attacks in
MO patients [42]. VIP infusion only induced dilation
of cranial arteries and mild headache [42]. To further
examine this issue, one MRA study investigated the
response to intravenous infusion of PACAP38 or VIP
in MO patients [34]. Sixteen out of 22 patients (73%)
reported delayed migraine-like attacks following
PACAP38 infusion, whereas only 4 out of 22 (18%)
did so after VIP infusion. Moreover, this study found
that both PACAP38 and VIP induced STA and MMA
dilation, while the MCA remained unaffected. The
PACAP38-induced vasodilation was longer-lasting (>
2 h) than the VIP-induced vasodilation which normal-
ized after 2 h. Interestingly, there was no difference
in arterial circumference between the pain and non-
pain side during PACAP38-induced migraine-like
attacks in 9 patients. Subcutaneous injection of suma-
triptan reduced headache intensity and caused con-
striction of only the extracranial arteries. Another key
finding from this study was that plasma levels of
PACAP38 were elevated in MO patients who devel-
oped migraine-like attacks compared to those who
did not 60 min after PACAP38 infusion. Since plasma
PACAP38 has a half-life of 3.5 min [24], a complete
clearance of exogenous PACAP38 is expected 60 min
after the start of infusion. To explain this, the authors
suggested three possible mechanisms [34]: 1) impaired
elimination; 2) endogenous release; 3) de novo syn-
thesis. However, when the data from this study [40]
was later pooled with data from a second study from
the same research group [43] to increase power and
sample size, there was no difference in pre-ictal
PACAP38 plasma levels between patients who devel-
oped migraine-like attacks (n = 39) compared to those
who did not (n = 15). To our knowledge, no study has
investigated the underlying mechanisms of PACAP38-
induced prolonged vasodilation.
A resting-state functional magnetic resonance imaging
(fMRI) study examined the involvement of specific
changes in cerebral network connectivity before and
during PACAP38-induced migraine-like attacks in MO
patients [44]. VIP was used as active placebo. Resting
state fMRI is a method to evaluate regional interactions
in cerebral connectivity when a subject is not perform-
ing an explicit task. Patients were scanned 30 min,
130 min, and 310 min after PACAP38-infusion, unless
they reported migraine-like attacks. In the event of
migraine-like attacks, immediate scans were performed.
The study found abnormal cerebral connectivity in all
the investigated cerebral networks (salience, sensori-
motor, and default mode) at the onset of migraine-like
attacks after PACAP38 infusion when compared to
outside of the attacks [44]. No alterations in cerebral
connectivity were found following VIP infusion. These
findings are interesting because those three networks
have been implicated in the processing of nociceptive
and emotional signals [45–48]. To solidify the import-
ance of these findings, the authors suggested that a simi-
lar experiment should be conducted before and at the
early phase of spontaneous migraine attacks.
One provocation study has also examined the inci-
dence of premonitory symptoms induced by intravenous
PACAP38 administration in MO patients [49]. Premoni-
tory symptoms occur hours to 2 days prior to the
migraine attack [28] and most commonly present them-
selves as unusual fatigue, neck stiffness, and poor con-
centration. It has previously been reported that 36% of
migraine patients experience premonitory symptoms fol-
lowing GTN infusion [50]. Following PACAP38-infusion
[49], 72% and 48% of the patients experienced migraine-
like attacks and premonitory symptoms, respectively.
Interestingly, CGRP did not induce premonitory symp-
toms in the same group of patients. In addition, there
was no difference of premonitory symptoms in patients
who developed attacks versus those who did not. These
findings are interesting because premonitory symptoms
are considered a marker of CNS involvement. However,
the study did not include a healthy control group or
placebo-treated patients. Therefore, we cannot exclude
that the observed association between PACAP38
infusion and premonitory symptoms could be due to
substance-related side effects.
As we reflect on the headache-inducing capabilities of
PACAP38, it is interesting that some MO patients de-
velop migraine-like attacks while others do not. The
question is whether fluctuating susceptibility could be
due to genetic variations among migraine patients.
Genetic studies have documented that genetic enrich-
ment of certain risk factor genes constitute a predispos-
ition to developing migraine [51–53]. To address this
issue, one study [54] stratified patients into two groups:
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one group with high family load (≥ 2 first-degree rela-
tives with MO) and one group with low family load (≤ 1
first-degree relatives with MO). In addition, genotyped
patients were stratified based on risk allele status. This
study revealed no association of hypersensitivity to mi-
graine following PACAP38 administration based on fam-
ily load and migraine-associated risk allele status in 32
genotyped MO patients.
Possible mechanisms of PACAP38-induced
migraine
Several possible mechanisms on the migraine-inducing
effect of PACAP38 have been suggested: vasodilatation
via cAMP, mast cell degranulation, parasympathetic in-
volvement, activation of sensory afferents by the cAMP-
signaling pathway or via the PAC1 receptor, and central
effects.
Vasodilation via cAMP
PACAP38 is a powerful dilator of cerebral arteries [29, 33]
and its effect is mediated through a cAMP-dependent sig-
naling pathway [15]. In relation to migraine, one human
experimental study provided evidence for cAMP upregu-
lation in migraine induction in MO patients after cilosta-
zol (phosphodiesterase 5 inhibitor) administration [28].
Interestingly, cilostazol is known to produce a long-lasting
dilation of cerebral arteries [55] and PACAP38 induces
long-lasting MMA-dilation (> 2 h) [34]. To what extent
the long-lasting MMA-dilation contributes to PACAP38-
induced migraine remains unknown.
Mast cell degranulation
Another interesting aspect to consider is the role of
mast cell degranulation in PACAP38-induced migraine.
Mast cells are found throughout the human organism
and play an important role in the immediate response to
hypersensitivity reactions [56]. Upon activation, mast
cells release soluble mediators (e.g. histamine, TNF-α,
and tryptase) into the circulation. Interestingly, hista-
mine induces migraine-like attacks in 70% of MO
patients [57]. Furthermore, mepyramine (a histamine H1
receptor blocker) pretreatment abolished both immedi-
ate and delayed histamine-induced migraine-like attacks
in the same group of MO patients [57]. In relation to
PACAP38, one in vitro study found that PACAP38 in-
duced mast cell degranulation in dural and peritoneal
mast cells in rats [58]. Furthermore, PACAP38-induced
MMA dilation was abolished in both mast cell depleted
and antihistamine pretreated rats [59]. Therefore, the
authors suggested that mast cell mediated histamine
release was implicated in PACAP38-induced MMA-
dilation [59]. In rats, mast cell degranulation activates
and sensitizes meningeal dural afferents [60]. Interest-
ingly, PACAP38 has a more potent degranulatory effect
on dural mast cells in rats compared with PACAP27 and
VIP [58]. Thus, it seems conceivable that the effect of
PACAP38 on mast cell degranulation is primarily medi-
ated through the PAC1 receptor because VIP had a lesser
effect on mast cells. However, the same study [58] also
found no effect of PAC1 receptor agonist (maxadilan) on
mast cells, while PAC1 receptor antagonism mediated
mast cell degranulation. Thus, it could be speculated
whether PACAP38 elicits its effect on mast cells through
a distinct target from the PAC1 receptor. In humans,
PACAP38-associated flushing and heat-sensation termi-
nated following anti-histamine treatment [29]. It should,
however, be noted that two human provocation studies
collected peripheral plasma levels of inflammatory mast
cell mediators (tumor necrosis factor alpha and tryptase)
in MO patients after PACAP38 infusion [34, 43]. These
studies found no changes in plasma tumor necrosis fac-
tor alpha and tryptase. Whether peripheral plasma
changes reliably reflect cranial release of mast cell medi-
ators remains unknown. Also, timing of collection might
play a role in detecting altered peripheral plasma levels
of mast cell mediators. Thus, mast cell degranulation
cannot be completely dismissed as a mediator in the
migraine-inducing mechanisms of PACAP38.
PACAP38 in the parasympathetic system
PACAP38 has been identified in both the sensory [6, 7]
and parasympathetic system [61]. The parasympathetic
distribution of PACAP38 stems from the sphenopalatine
and otic ganglia [9], as well as from parasympathetic
perivascular nerve fibers [62]. It has been suggested that
parasympathetic efferent fibers play a role in the trigemi-
novascular system by releasing neuropeptides, such as
PACAP38, involved in nociceptive transmission [63].
Interestingly, VIP is also present in both the sphenopala-
tine and otic ganglia [64], but no VIP immunoreactivity
has been found in the trigeminal ganglion [65]. These data
indicate that PACAP38 has two sites of origin unlike VIP:
the parasympathetic system and the sensory system. In this
context, it is also interesting that the PACAP and VIP
molecules are parasympathetic biomarkers and both
are less prominently expressed in the dura mater and
trigeminal ganglion compared with CGRP, while being
more prominently expressed in cerebral vessels [66].
Therefore, the authors speculated that PACAP has a
larger parasympathetic distribution and a minor sen-
sory distribution. These data suggest PACAP38 might
function primarily as a neuropeptide in parasympa-
thetic pathways underlying migraine, while CGRP acts
as a neuropeptide in sensory pathways underlying
migraine. However, to what extent parasympathetic ef-
ferent fibers play a role in PACAP38-induced migraine
remains a subject for further investigation.
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Activation of sensory afferents by the cAMP-signaling
pathway or via the PAC1 receptor
In the sensory nervous system, PACAP38 is present in
first-order neurons in the trigeminal ganglion [6] and in
second-order neurons in the TNC [7]. All three PACAP38
receptors upregulate cAMP [14] and PACAP38 receptors
have been detected in both the trigeminal ganglion [13]
and TNC [67]. In view of findings from human experi-
mental data, migraine-like attacks after PACAP38 infusion
could be explained by modulation of dural or extracranial
trigeminal nociceptors outside of the BBB [68]. The pres-
ence of all PACAP38 receptors has been identified in the
vessel wall of human cerebral arteries [13]. Hence, it could
be speculated that PACAP38 upregulates intracellular
cAMP in trigeminal nociceptors following PAC1 receptor
activation. This mechanism could possibly initiate a
neurobiological cascade resulting in migraine attack devel-
opment. Indeed, CGRP and cilostazol also upregulate
intracellular cAMP [69, 70] and both are potent triggers
of migraine-like attacks in MO patients [28, 71]. In this
context, it is interesting that elevated intracellular cAMP
levels have been associated with activation of trigeminal
neurons [72] and meningeal nociceptors [73]. Given that
both PACAP38 and CGRP act on cell membrane recep-
tors one would expect a similar median time to migraine
onset after infusion. However, direct comparison of differ-
ent groups of patients is problematic. To directly compare
PACAP38 and CGRP migraine responses would require
head to head comparison in the same group of patients.
To date, this has not been investigated. One ongoing RCT
is currently investigating the ability of CGRP blockade to
prevent PACAP38-induced migraine [74].
PACAP38 and central effects
It has been reported that PACAP38 is able to cross the
BBB by a saturable transport mechanism [75] and that
0.053% of PACAP38 passes the BBB after 5 min follow-
ing intravenous infusion [76]. Animal models have im-
plicated PACAP38 in central nociceptive transmission
[77] and in rats intrathecal capsaicin elevated PACAP
levels in the cerebrospinal fluid [78]. Hence, spinal cord
C-fibers might release PACAP upon activation. Therefore,
PACAP38 might modulate nociceptive input through its
PAC1 receptor which is expressed on second-order
trigeminal neurons [7]. Furthermore, the hypothalamus
contains the most abundant population of PACAP38-
containing neurons [79] and its activation has previ-
ously been associated with premonitory symptoms in
GTN-provoked migraine attacks [80]. Interestingly,
MO patients reported premonitory symptoms after
PACAP38 infusion [49]. Yet, we do not have suffi-
cient data to confirm or refute a central effect of
PACAP38-induced migraine-like attacks.
Discussion and future perspectives
The human experimental studies have demonstrated the
potency of PACAP38 as a pharmacological “trigger” of
migraine-like attacks [29, 34, 44, 49, 54]. Yet, there are
several methodological limitations and aspects worth
pointing out that should be optimized in future study
designs. In the following, we will discuss: 1) Plasma
PACAP38 as a biochemical marker in human experimen-
tal models; 2) heterogeneity of the PACAP38 response in
MO patients; 3) MRA biomarkers of PACAP38-induced
migraine-like attacks; 4) future experimental models using
PACAP27.
PACAP38 as a biochemical marker
In migraine patients, PACAP38 plasma levels have been
measured during both spontaneous [81, 82] and
PACAP38-induced [43] migraine attacks. Tuka et al. [81]
reported elevated ictal PACAP38 plasma levels during
spontaneous migraine attacks relative to interictal
PACAP38 plasma levels. Migraine sufferers also had lower
interictal PACAP38 plasma levels compared with healthy
controls. Another study reported elevated PACAP38
plasma levels during migraine attacks and found that sub-
sequent sumatriptan administration was associated with a
decrease in PACAP38 plasma levels [82]. In contrast,
pooled data analysis from two PACAP38 provocation
studies found no pre-ictal phase increase in PACAP38
plasma levels in MO patients who experienced migraine-
like attacks [37]. The conflicting data could be explained
by assay variation [82–84] and differences in timing of
measurements. It is also debatable whether peripheral
plasma measurements reliably reflect cranial PACAP38
release and therefore the jugular vein might constitute a
more precise site of collecting blood samples. It should be
noted that one study reported no difference in extracranial
and cranial CGRP plasma levels in healthy volunteers [85].
In addition, two of the studies [81, 82] included both MO
patients and migraine with aura (MA) patients. Thus, a
different PACAP-response cannot be excluded in MO pa-
tients compared with MA patients. For future human
provocation studies, it would be interesting to measure
PACAP38 plasma levels after sumatriptan administration
when using PACAP38 or other pharmacological “triggers”
such as CGRP and cilostazol. Here, it would be important
to have a placebo-controlled design; otherwise, PACAP38
could possibly decrease spontaneously over the course of
a migraine attack. The exact antimigraine mechanism of
sumatriptan remains unknown; thus, it could be specu-
lated that a reduction in PACAP38 plasma levels might
play a role.
Heterogeneity of the PACAP38 response in MO patients
Human experimental studies have revealed a heteroge-
neous PACAP38 response in MO patients in that some
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develop migraine-like attacks while others do not
(Table 1). In a total of three PACAP38 provocation stud-
ies, 46 out of 66 (70%) MO patients experienced
migraine-like attacks (Fig. 1). Giving this evidence, the
question is whether susceptibility to migraine follows a
fluctuating pattern. Indeed, two studies suggested that
the likelihood of migraine attack development exhibits
innate variations [86, 87] – suggesting a migraine
threshold that varies over time. Thus, it raises the issue
of whether PACAP38-induced migraine-like attacks can
only be induced at certain points in a migraine suscepti-
bility cycle. This seems questionable because a small
PACAP38 dose-response pilot study found that PACAP-
induced migraine-like attacks seem to be reproducible in
MO patients [26]. Furthermore, the large sample size of
MO patients who developed migraine-like attacks after
PACAP38 infusion (46 out of 66) deem it improbable
that all 46 patients were in a migraine susceptible phase.
To dissect this issue, MO patients with few attacks on a
yearly basis should undergo PACAP38 provocation to
clarify the importance of possible cyclic migraine induc-
tion variability. In relation to this, one provocation study
[88] found no relation between headache frequencies in
MO patients and GTN-induced headache.
Future provocation reproducibility studies should also
include a three-arm crossover design with subjects ran-
domized to PACAP38; PACAP38; Placebo. This would
permit blinded assessment of PACAP38 reproducibility
while controlling for placebo response. Following this,
phenotyping migraine sufferers in PACAP38 responders
versus non-responders could be used to possibly predict
efficacy of drugs targeting the PACAP38 molecule or its
PAC1 receptor. This would delineate PACAP38 as a
reliable biomarker of the migraine. Future studies should
also investigate whether blockade of PACAP38 or its
PAC1 receptor may prevent the migraine-inducing ef-
fects of PACAP38. Moreover, studies in MA and FHM
patients are needed to cover the whole migraine
spectrum with respect to PACAP38 provocation. The
same need exists for PACAP38 provocation studies in
cluster headache and tension-type headache patients.
Magnetic resonance imaging
Advanced brain imaging in human experimental models
provides a unique opportunity to identify biomarkers spe-
cific to primary headaches. PACAP38 provocation studies
have demonstrated neuronal and vascular changes taking
place in the brains of migraine sufferers both ictally and
interictally. For this reason, future studies should investi-
gate whether PACAP38 or PAC1 receptor blockade is able
to prevent PACAP38-induced MMA dilation. If this
proves to be the case, the question is whether blockage of
MMA dilation co-occurs with blockage of PACAP38-
induced migraine-like attacks. This would in particular be
interesting in a population of migraine patients that have
previously been stratified as PACAP38 responders.
PACAP27 as pharmacological “trigger” of primary
headaches
The migraine-inducing effects of PACAP38 have been
well-documented but to date no study has investigated
the migraine-inducing effect of PACAP27. It is the less
Table 1 Overview of PACAP38 provocation studies in migraine
without aura (MO) patients
Reference Study
design
Number of MO
patients who
developed
migraine-like
attacks
Total
number
of MO
patients
Major
findings
Schytz et al. [29] Double-blind
crossover
7 12 PACAP38 induces
migraine-like attacks
Amin et al. [34] Double-blind
randomized
16 22 PACAP38-induced
migraine is
associated with
sustained dilation of
extracranial arteries
Amin et al. [44] Double-blind
crossover
18 24 PACAP38-induced
migraine-like attacks
is associated with
altered functional
cerebral connectivity
Guo et al. [49] Double-blinded 23 32 PACAP38 induces
premonitory
symptoms
Guo et al. [54] Double-blinded 23 32 PACAP38 response
is not associated
with high family
load or risk allele
status
Fig. 1 Proportion (median and range) of patients who developed
migraine-like attacks and of patients who did not develop migraine-
like attacks after PACAP38 infusion [29, 34, 54]
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abundant bioactive form of the PACAP molecule, but
displays similar affinity to the PAC1 receptor as
PACAP38 [89]. Interestingly, the role of the 28-to-38
segment of the PACAP molecule seems to be important
for two reasons. First, one study [90] indicated that the
28-to-38 segment could possibly play a role for the BBB
transporter to recognize and transport the PACAP mol-
ecule across the BBB. Secondly, PACAP38 has a half-life
of less than 5 min in human plasma in vitro, while
PACAP27 displays a relative lack of degradation [91].
For these reasons, it would be relevant to investigate the
response to PACAP27 provocation in migraine and
cluster headache patients.
Conclusion
Great advances have been made over the past decade in
understanding the pathophysiology of migraine using
PACAP38 as a pharmacological “trigger”. Knowledge ac-
quired from these human experimental studies has shed
light on the PACAP38 molecule or its PAC1 receptor as
potential therapeutic drug targets. Nonetheless, the
PACAP38 migraine-specific mechanisms of action have
not been fully clarified and its involvement in cluster
headache and tension-type headache remains a subject
for investigation. Future studies will seek to refine design
and execution; thereby, paving the way to delineate
biomarkers of primary headache disorders.
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